Lv51
918 积分 2023-11-09 加入
CDK inhibitors from past to present: A new wave of cancer therapy
1个月前
已完结
Advances in Structural Types and Pharmacochemistry of CDK12 Inhibitors
1个月前
已完结
Current progress and novel strategies that target CDK12 for drug discovery
1个月前
已完结
Combination therapy and dual-target inhibitors based on cyclin-dependent kinases (CDKs): Emerging strategies for cancer therapy
1个月前
已完结
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor
1个月前
已关闭
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor
1个月前
已关闭
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor
1个月前
已关闭
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor
1个月前
已关闭
The emergence of pan-KRAS drugs
1个月前
已完结
Discovery of 4-(2-(methylamino)thiazol-5-yl)pyrimidin-2-amine derivatives as novel cyclin-dependent kinase 12 (CDK12) inhibitors for the treatment of esophageal squamous cell carcinoma
1个月前
已完结
皖公网安备34019202002308
